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Background
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized 
by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal an-
tibody against the terminal complement protein C5, potently reduces chronic intra-
vascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with 
eculizumab in 6 Korean patients with PNH.
Methods
We enrolled 6 patients with PNH who had clinically significant hemolysis. Eculizumab 
was administered intravenously at 600 mg/week for the first 4 weeks followed by 900 
mg at week 5 and 2nd weekly thereafter. 
Results
Three men and 3 women with a median age of 39.5 years (24-61 years) were enrolled. 
The median duration of PNH was 11 years (6-25 years). Hemolysis occurred in all patients 
[median lactate dehydrogenase (LDH) level, 7.95 times the upper limit of the reference 
range of LDH]. All patients treated with eculizumab had a rapid and sustained reduction 
in the degree of hemolysis. RBC transfusion requirements for 3 months were decreased 
from 0-12 units (median requirement, 1.5 units) to 0-6 units (median requirement, 0 
units). Improvement in fatigue was noted in 4 patients. Further, 5 patients who had been 
receiving corticosteroids either reduced the dose or discontinued therapy. No significant 
adverse events related to eculizumab therapy were observed.
Conclusion
These results show that eculizumab reduces the degree of intravascular hemolysis, re-
duces or eliminates the requirement of RBC transfusion, and improves anemia and fatigue 
in patients with PNH. Eculizumab is an effective and safe option for treating Korean pa-
tients with PNH.
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INTRODUCTION
  Paroxysmal nocturnal hemoglobinuria (PNH) is an ac-
quired clonal disorder caused by a somatic mutation in the 
phosphatidylinositol glycan-complementation class A (PIG- 
A) gene in hematopoietic stem cells [1-3]. Patients with 
PNH present with intravascular hemolytic anemia, bone 
marrow failure, and thrombosis. Many of the clinical mani-
festations of PNH result from complement-mediated intra-
vascular hemolysis. The life-threatening condition of throm-
boembolism (TE) is the most common cause of death in 
patients with PNH, at least in Western populations (TE ac-
counts for 40-67% of patient deaths in these populations) 
[1-3]. On the other hand, the incidence of TE is much lower 
in Asian countries [2, 3]. Previously, the management of 
PNH had been palliative and non-targeted, and it focused 
on treating the symptoms of anemia and episodic hemolysis Korean J Hematol 2010;45:269-74.
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rather than the underlying chronic hemolysis associated with 
disease progression. Presently, allogeneic bone marrow trans-
plantation (BMT) is the only curative therapy for PNH. 
Available supportive care options include blood transfusions 
and nonspecific drug treatments including, but not limited 
to, steroids and anticoagulants [4, 5]. The results of a retro-
spective analysis of 286 PNH patients from a national registry 
in South Korea indicated that the cumulative incidence of 
TE was 15%; TE was a strong predictor of mortality [6]. 
Despite medical intervention with supportive care (78% of 
the patients used corticosteroids), patients continued to show 
disabling symptoms, progressive complications, and early 
mortality [7]. 
  Eculizumab (Soliris
Ⓡ; Alexion Pharmaceuticals, Inc., Che-
shire, CT, USA), a humanized monoclonal antibody against 
the terminal complement protein C5, has a direct and potent 
effect on chronic intravascular hemolysis [4, 5, 8]. In 2007, 
the US Food and Drug Administration approved the use 
of eculizumab against PNH on the basis of its efficacy in 
2 phase 3 clinical trials [9-11]. Eculizumab is highly effective 
in reducing intravascular hemolysis in PNH patients, and 
treatment with eculizumab decreases or eliminates the need 
for blood transfusions; improves the quality of life; and re-
duces pulmonary hypertension, chronic kidney disorders, 
and the risk of thrombosis [9-11]. In this study, we tested 
the clinical efficacy and safety of eculizumab for treating 
Korean patients with PNH. We report the results of a 
24-week treatment with eculizumab.
MATERIALS AND METHODS
  A total of 6 Korean patients with PNH, who were selected 
from 5 institutions and had clinically significant hemolysis, 
received eculizumab therapy. This study was initiated in 
December 2009 and is currently ongoing. Patients who were 
≥18 years of age, had a PNH granulocyte proportion of 
≥10%, and had lactate dehydrogenase (LDH) levels of at 
least 1.5 times the upper limit of the reference range (ULN) 
of LDH were eligible. Further, patients with a history of 
thrombosis or associated symptoms were included in this 
study. Patients receiving stable doses of anticoagulants, iron 
supplements, and immunosuppressive drugs, including corti-
costeroids, were also included. Patients were excluded, if 
the platelet count was ＜20×10
9/L; absolute neutrophil count 
(ANC), ＜0.5×10
9/L; and corrected reticulocyte count, ＜1%. 
Patients with complement deficiency, active bacterial in-
fection, prior meningococcal disease, or prior hematopoietic 
stem cell transplantation were also excluded.
  Eculizumab was administered intravenously at a dose of 
600 mg/week (±2 days) for the first 4 weeks 900 mg at 
week 5 and 2
nd weekly thereafter. Two weeks before the 
therapy was initiated, all patients were vaccinated against 
Neisseria meningitidis, because the inhibition of complement 
C5 increases the risk of developing neisserial infections. 
Throughout the study, the patients received RBC trans-
fusions, if the transfusions were medically indicated. In ac-
cordance with the Declaration of Helsinki, written informed 
consent was obtained from all patients prior to their enrol-
ment in this study.
  We obtained the following information of the patients: 
baseline clinical characteristics; demographics, laboratory 
values; LDH, RBC, Hb, reticulocyte, WBC, ANC, platelet, 
creatinine level, PNH clone size, medical history, symptoms, 
history of TE, and treatment history. We regularly checked 
the Hb levels and degree of hemolysis by measuring the 
LDH levels, and collected information regarding any adverse 
events at each dosing visit. We evaluated the degree of fatigue 
by using the validated Functional Assessment of Chronic 
Illness Therapy-Fatigue (FACIT-Fatigue) instrument [12] 
from baseline. Total scores on the FACIT-Fatigue instrument 
range from 0 to 52, with higher scores indicating an improve-
ment in fatigue. An increase of ≥3 points is considered 
clinically significant for this instrument [12].
RESULTS
1. Patient characteristics
  Three men and 3 women with a median age of 39.5 years 
(24-61 years) were enrolled in this study. The median dura-
tion of PNH was 11 years (6-25 years). All patients were 
diagnosed with PNH on the basis of flow cytometric analysis 
of WBCs (CD59). The PNH clones in all patients were large 
(median granulocyte clone size, 94.75%; range, 77.3-99%). 
Of the 6 patients, 2 were previously diagnosed with aplastic 
anemia (PNH/aplastic anemia); the other 4 had classic PNH. 
All the patients had anemia (median Hb, 8.15 g/dL; range, 
6.8-12.5 g/dL). Median neutrophil and platelet counts were 
1.38×10
9/L [range, (0.9 to 4.68)×10
9/L] and 1.01×10
11/L 
[range, (0.42 to 2.19)×10
11/L], respectively. Further, 4 patients 
had thrombocytopenia [platelet count, (0.42 to 1.2)×10
11/L] 
and 2 had neutropenia (WBC count, ＜4.0×10
9/L). Before 
treatment with eculizumab, 5 patients had received RBC 
transfusions and 5 had been treated with corticosteroids; 
none were treated with immunosuppressive agents. More-
over, 2 patients had a history of thrombosis, and 1 patient 
had been receiving warfarin. Hemolysis was noted in all 
patients, and it was evaluated by the levels of LDH (median 
LDH level, 7.95 times the ULN of LDH; range, 3.5-12.4 
times) (Table 1). Furthermore, all the patients had fatigue 
and hemoglobinuria, before eculizumab therapy was initiated. 
Severe fatigue was noted in 4 patients, and severe abdominal 
pain in 3 patients (Table 2).
2. Efficacy of eculizumab
1) Reduction in the degree of hemolysis
  Of the 6 patients, 5 completed the 24-week therapy with 
eculizumab. The sixth patient completed only 12 weeks of 
treatment, because he was enrolled later than the other 
patients. All patients treated with eculizumab had a rapid 
and sustained reduction in the degree of hemolysis. The 
reduction was evaluated by the change in LDH levels, and 
this reduction was observed in all patients (median reduction Korean J Hematol 2010;45:269-74.
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Table 1. Summary of PNH patients.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Clinical characteristics
Gender Female Male  Male  Male  Female  Female 
Age (years) 24 30 61 45 34 45
Duration of disease (years) 6 7 15 15 6 25
History of thrombosis No No Yes No No Yes
Associated bone marrow disorders None None None Aplastic aanemia Aplastic aanemia None
Laboratory values
PNH clone size (%)
a) 94 90  77.3 95.5 99 97.7
LDH
b) (times) 12.4 9.0 4.6 7.3 3.5 8.6
RBC (×10
12/L) 2.63 2.49 3.79 2.51 2.13 2.97
Hemoglobin Hb (g/dL) 8.1 8.2 12.5 7.0 11.6 6.8
Reticulocyte count (%) 6.95 5.07 3.37 11.5 17.8 10.27
WBC count (×10
9/L) 4.35 6.08 4.4 2.9 3.63 10.9
ANC (×10
9/L) 1.35 4.68 3.26 1.42 1.21 0.9
Platelet count (×10
9/L)) 167 120 62 42 83 219
Creatinine level (mg/dL) 0.38 0.54 2.00 0.90 0.71 0.80
Previous treatments
Transfusion history in the past
3 months (units)
2 1 1 12 None 2
Prednisolone (mg/day) 15-30 15-30 15 None 10 60
Warfarin (mg/day) None None None None None 4
Oxymetholone (mg/day) None 50 None None None 50
a)Clone size was measured by determining the PNH granulocyte proportion by using flow cytometric analysis (CD59), 
b)LDH concentrations
are expressed as multiples of the upper limit of the normal reference range of LDH.
Abbreviations: LDH, lactate dehydrogenase; ANC, absolute neutrophil count.
Table 2. Symptoms related to PNH during the eculizumab therapy.
　 　 Headache Fatigue
Abdominal
 pain




Patient 1 Pre-Tx Slight Severe Slight Mod Mod Severe Slight
　 24 wk No Mod No Mod No Slight No
Patient 2 Pre-Tx Slight Severe No Slight No Mod No
　 24 wk Slight Slight No Slight Slight Mod No
Patient 3 Pre-Tx Slight Mod Severe Mod Slight Mod Slight
　 24 wk No Slight No No No Slight No
Patient 4 Pre-Tx Mod Severe No Mod Slight Mod Slight
　 24 wk No Mod No Slight Mod Mod No
Patient 5 Pre-Tx Mod Slight Severe Slight No Mod No
　 24 wk Mod Severe Slight Slight Slight Mod Slight
Patient 6
a) Pre-Tx Slight Severe Very severe Severe No Very severe No
　 12 wk No No No No No No No
a)This patient received eculizumab therapy for only 12 weeks.
Abbreviations: Pre-Tx, pretreatment of with eculizumab; Mod, moderate.
at 24 weeks, 84.5%; range, 69-88%) (Table 3). In all the 
patients, the decrease in the LDH levels began after they 
received a single dose of eculizumab, and LDH levels re-
mained within or just above the reference range during 
eculizumab therapy (Fig. 1). The median LDH level at 24 
weeks was 1.25 times the ULN of LDH. The reduction in 
the degree of hemolysis resulted in an improvement in ane-
mia, and the median Hb level at 24 weeks was 10.2 g/dL 
(range, 6.9-12.4 g/dL). During the 3 months preceding enroll-
ment, the RBC transfusion requirement of the patients was 
0-12 units (median requirement, 1.5 units), whereas during 
the first 3 months of this study, the range was reduced 
to 0-6 units (median requirement, 0 units). Only 1 patient 
who had PNH/aplastic anemia remained transfusion-depend-
ent (Fig. 2). However, the units transfused were reduced 
from 12 units/3 months before treatment to 6 units during Korean J Hematol 2010;45:269-74.
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Table 3. Clinical effectiveness of eculizumab.
1 2 3 4 5 6
a)
Hemolysis (measured by LDH levels)
LDH reduction (%)  88 87 84 82 69 85
LDH at 24 weeks of treatment
b) (times) 1.1 1.2 0.8 1.3 1.4 1.3
Anemia/Transfusion
Reduction in Ttransfusion requirement  reduction (%) 100 100 100 50 100 100
U n i t s  o f  R B C t r a n s f u s i o n  f o r  3  m o n t h s  o f  e c u l i z u m a b  t h e r a p y  ( u n i t s ) 000600
Hb level at 24 weeks of treatment (g/dL) 10.0 10.4 12.4 6.9 10.6 7.1
Fatigue (measured by the FACIT-Fatigue instrument)
Fatigue level at 12 weeks of treatment  15 8 -1 -8 4 18
Fatigue level at 24 weeks of treatment  16 12 4 0 -7 None
a)This patient received eculizumab therapy for only 12 weeks, 
b)LDH concentrations are expressed as multiples of the upper limit of the normal
reference range of LDH.
Abbreviations: LDH, lactate dehydrogenase; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; Hb, hemoglobin.
Fig. 1. Changes in the levels of lactate dehydrogenase during treatment
with eculizumab. Abbreviations: LDH, lactate dehydrogenase; ULN, 
upper limit of the normal reference range.
Fig. 2. Reduction in the number of units of red blood cell transfused 
during treatment with eculizumab.
the initial 3 months of treatment (50% reduction).
2) Improvement of clinical symptoms
  Fatigue was assessed by using the FACIT-Fatigue instrument. 
Improvement in fatigue was noted in 4 patients (67%). The 
FACIT-Fatigue scores improved by a median of 8 points 
during the first 24 weeks of eculizumab therapy, and only 
1 patient had decreased scores after therapy (Table 2). 
Further, after the therapy, significant improvement in ab-
dominal pain was noted in the 3 patients who had severe 
abdominal pain before treatment (Table 2).
3) Reduction or discontinuation of concomitant medi-
cation
  One patient who had been receiving warfarin for prevent-
ing further thrombotic events discontinued the anticoa-
gulation therapy after the initiation of eculizumab therapy. 
Moreover, after starting eculizumab therapy, 5 patients who 
were being treated with corticosteroids reduced the dose 
of the corticosteroid (N=1, prednisolone dose was reduced 
from 60 mg/day to 3-12 mg/day) or discontinued the cortico-
steroid therapy (N=4). 
3. Adverse events during treatment with eculizumab
  There were no significant adverse events related to eculizu-
mab therapy. Mild to moderate headache was noted in 2 
patients, and mild abdominal pain in only 1 patient (Table 
2). Only 1 patient had a moderate degree of nausea and 
vomiting. There were no cases of severe systemic infections. 
None of the patients developed new thrombotic events dur-
ing the course of the treatment. 
DISCUSSION
  PNH is a chronic, often fatal disease characterized by 
symptoms of fatigue and intermittent episodes of dysphagia, 
abdominal pain, and hemoglobinuria [1]. The median surviv-Korean J Hematol 2010;45:269-74.
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al time after diagnosis is about 10 years. The life-threatening 
condition of TE is the most fatal complication of PNH [1-3]. 
Presently, allogeneic BMT is the only curative therapy for 
PNH, but this therapy is associated with significant morbidity 
and mortality. The International Bone Marrow Transplant 
Registry reported that the 2-year survival probability was 
56% in 48 recipients of HLA-identical sibling BMT between 
1978 and 1995 [13]. Therefore, supportive treatments, includ-
ing RBC transfusion and corticosteroid therapy, have been 
generally used for reducing the symptoms in PNH patients. 
However, these medical interventions cannot prevent the 
progressive complications and early mortality associated with 
this disease [1-3]. 
  Eculizumab is a humanized monoclonal antibody that pre-
vents the activation of complement C5 and the subsequent 
formation of the cytolytic membrane attack complex of 
complement. Since the introduction of eculizumab for the 
treatment of PNH, few cases from Asian countries have 
been reported. In this study, we evaluated the safety and 
efficacy of eculizumab for treating Korean patients with 
PNH. No serious infusion-related problems were noted dur-
ing the treatment period. We confirm that both the pre-
viously recommended dose and administration interval of 
eculizumab are safe and well tolerated in Korean patients 
with PNH. 
  We observed rapid and sustained reduction of LDH levels 
to, or just above, the ULN of LDH during eculizumab therapy 
in Korean patients with relatively large PNH clones (median 
granulocyte clone size, 94.75%). The median LDH level de-
creased from 7.95 times the ULN of LDH at baseline to 
1.25 times the ULN at 24 weeks. The reduction in the degree 
of hemolysis after eculizumab therapy was associated with 
a significant improvement in anemia, which was indicated 
by a rise in the Hb level from a median level of 8.15 g/dL 
at baseline to 10.2 g/dL at 24 weeks. We also observed stabili-
zation of the number of RBC units transfused. Among the 
2 patients who were previously diagnosed with PNH/aplastic 
anemia, 1 patient remained transfusion-dependent during 
eculizumab therapy (1/6). However, the RBC units transfused 
were reduced from 12 units/3 months before treatment to 
6 units during the initial 3 months of treatment (50% reduc-
tion). In the open-label, 52-week, Phase 3 study (SHEPHERD) 
[11], the reductions in transfusion were observed even in 
patients with baseline platelet counts of ＜65×10
9/L. These 
data suggest that patients with both classic PNH and PNH 
associated with other bone marrow failure syndromes will 
benefit from eculizumab therapy. However, when appro-
priate, young PNH patients with life-threatening cytopenias 
(e.g., severe aplastic anemia) should be recommended alloge-
neic BMT.
  Fatigue is a common symptom in patients with PNH, 
and it occurs not only because of anemia but is also closely 
linked to hemolysis and nitric oxide depletion due to chronic 
hemolysis [1, 2]. In previous trials, the FACIT-Fatigue scores 
significantly improved within 1 week of treatment (median 
increase, 3 points), and this effect sustained throughout a 
period of 52 weeks (overall median increase, 10 points) [11]. 
A change of ≥3 points on the FACIT-Fatigue instrument 
is considered clinically significant [12]. We observed a sig-
nificant improvement in the FACIT-Fatigue scores of 4 pa-
tients after eculizumab therapy (median increase at 24 weeks, 
8 points), but the scores of 1 patient decreased, and this 
change should be further evaluated with longer follow-up.
According to previous clinical trials, headache occurs in ap-
proximately 50% of the patients during eculizumab therapy 
[11]. We noted 2 cases (33%) of mild to moderate headache 
in this study. Although neisserial sepsis was the most serious 
complication and other infections were a common side effect 
of eculizumab therapy, previous clinical trial data suggest 
that the infections were mild to moderate in nature and 
not related to eculizumab therapy [9-11]. In this trial, we 
could not find clinically significant infections during eculizu-
mab therapy. As there were no significant adverse events 
and no newly developed TE events during the eculizumab 
therapy, eculizumab treatment appeared to be safe in Korean 
patients with PNH.
  After eculizumab therapy, 5 patients who were being treat-
ed with corticosteroids reduced the dose of the corticosteroid 
(N=1) or discontinued corticosteroid therapy (N=4); hence, 
eculizumab therapy may reduce or eliminate the serious 
side effects of corticosteroids in patients with PNH. Previous 
clinical trials have shown that the TE event rate showed 
a significant reduction in 24 weeks during eculizumab treat-
ment (92%) than in the same time period before treatment 
[10, 11]. The discontinuation of the anticoagulation therapy 
after the initiation of eculizumab therapy in patients with 
a history of TEs is still controversial. Only 1 patient who 
had been receiving warfarin before eculizumab therapy dis-
continued the medication during the therapy. Thus, eculizu-
mab may reduce or eliminate the several serious toxicities 
associated with anticoagulation therapy in patients in whom 
the therapy was discontinued.
  In conclusion, this study is the first report on the efficacy 
and safety of eculizumab for treating Korean patients with 
PNH. This study showed that eculizumab reduced both the 
degree of intravascular hemolysis and the need for RBC 
transfusion. Further, improvements in anemia, fatigue, and 
quality of life were noted after eculizumab treatment. 
However, the long-term efficacy and safety of eculizumab 
should be further evaluated in a larger study population.
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